Key takeaways
Jardiance (empagliflozin) and Afrezza (insulin human inhaled are both used to manage diabetes, but they work in different ways and have distinct features. Jardiance is a sodium-glucose co-transporter 2 (SGLT2) inhibitor taken orally once a day for type 2 diabetes only, which helps lower blood sugar by causing your body to excrete excess sugar through urine. It also has benefits for heart failure and chronic kidney disease. Afrezza, on the other hand, is a fast-acting insulin for both type 1 and type 2 diabetes that you inhale before meals to help your body absorb and store sugar from your bloodstream. Unlike Jardiance, Afrezza is not suitable for people with breathing problems like asthma or chronic obstructive pulmonary disease (COPD). Jardiance can cause urinary tract and yeast infections, while Afrezza's common side effects include low blood sugar, cough, and throat irritation. Currently, Jardiance does not have a generic version available until at least 2025, whereas Afrezza is only available in its branded form.
Prices with our coupons for Jardiance vs. Afrezza
